Xilio Therapeutics – In February, 2021 AskGene Pharma signed a patent cross-licensing agreement with Xilio Therapeutics of Waltham, Massachusetts for the development, production, and commercialization of cytokine-based products for oncology indications. As part of the agreement, Xilio gained access to a part of AskGene’s cytokine prodrug IP. In return, AskGene receives the rights to develop, produce, and commercialize the products in the Asia Pacific region (except Japan).
A partnership with AskGene Pharma offers the opportunity to work with some of the most experienced and innovative scientists in the cytokine prodrug space. Our SmartKine® platform offers significant advantages over other cytokine-based technologies. Learn more about our science and technology
We are particularly interested in partnering with organizations seeking to advance the development and commercialization of targeted immunotherapy treatments for oncology and autoimmune indications.
"*" indicates required fields